Transforming Vaccine Design with T Cell Activation for Infectious Diseases and Virus-Induced Cancers.
Addressing virus variability with invariable epitopes and modular solutions for T cell control.
Cell-Immune Pharma pioneers a breakthrough in vaccine design by leveraging T-cell activation to combat virus variability. Our proprietary 3-step program delivers scalable solutions that enhance adaptability and durability in vaccine development.
The Challenge
Viruses evolve.
Vaccines fall behind.
Rapid viral mutation leads to seasonal variability and immune escape. Current vaccines rely mainly on antibody-based immunity, which often falls against emerging strains.
Learn more about the challengeVirus Evolution
High mutation rate leads to new variants and immune escape.
Stable Epitopes
Conserved regions remain unchanged across variants.
Our Solution
Target what
doesn’t change.
We target conserved viral epitopes and activate T cells to deliver broad, durable, and long-term immune protection across variants and pathogens.
Discover our solutionThe good thing about science is that it’s true whether or not you believe in it.— Neil deGrasse Tyson
The Gap in Current Vaccines
In current vaccines, relevant targets are absent to trigger a powerful T cell response, so it’s mostly absent.
Antibody response (limited)
T cell response (powerful & durable)
Our Platform
A 3-Step Proprietary Platform for Next-Generation Vaccines
We integrate natural immune recognition, biological validation, and modular vaccine design to identify the right targets and build vaccines that are adaptable, scalable, and built for the future.
How It WorksIDENTIFY
We identify invariable epitopes recognized by T cells in people with natural immunity.
VALIDATE
We validate targets using advanced assays and immune profiling technologies.
DESIGN
We design modular vaccine constructs to induce robust and lasting T cell responses.
Leadership
Experienced. Passionate. Committed.
Our team brings deep expertise in immunology, drug development, and biotechnology to advance the next generation of vaccines.

David Lapointe
Chief Executive Officer

Dr. Réjean Lapointe, Ph.D.
Chief Scientific Officer
Co-founder

Dr. Jean-François Cailhier, M.D. Ph.D.
Chief Medical Officer
Co-founder
Partner With Us
Let’s build the future of vaccines together.
We welcome collaborations, partnerships, and inquiries from organizations that share our mission.



